Research Opportunity Announcements

A Research Opportunity Announcement (ROA) is a public document that announces the availability of an Other Transaction (OT). It provides the initiative’s purpose, type of award, instructions on how to apply, due date for proposals or applications, and research opportunity number.

Information about Other Transactions can be found on the NIH Grants & Funding website.

File
This is a preview of the Data Table. Only the first three rows are displayed.
Title OTA Number Purpose OTA Category Contact
HEAL Initiative: EPPIC-Net Pain Research Asset Application (OT2) OTA-22-002 The purpose of this research opportunity announcement (ROA) is to invite Stage 1 preliminary applications for submission of therapeutics, including but not limited to, drugs, biologics, and devices as well as biomarkers (termed assets) for study in the HEAL Initiative’s EPPIC-Net. HEAL/EPPIC-Net Barbara Karp, MD
HEAL Initiative: EPPIC-Net Pain Research Asset Application- Dossier OTA-23-005 The purpose of this research opportunity announcement (ROA) is to invite Stage 2 Dossier applications for submission of assets that have successfully passed Stage 1 preliminary application review. EPPIC-Net applications are reviewed in a three-stage process. applications to Stages 2 & 3 will be by invitation only. HEAL/EPPIC-Net Barbara Karp, MD
HEAL Initiative: EPPIC-Net Pain Research – Application for Clinical Trials and Related activities (OT2) OTA-23-006 The purpose of this research opportunity announcement (ROA) is to fund early phase clinical trials of pain therapeutic assets and its related activities. The ROA accepts applications from the EPPIC-Net CCC, working in conjunction with the EPPIC-Net DCC and SCCs, for funding of clinical trial preparatory activities not covered by EPPIC-Net U24 agreements to the CCC, DCC, or Specialized Clinical Centers (Hubs/Spokes), as well as applications for specific clinical trials. HEAL/EPPIC-Net Barbara Karp, MD
StrokeNet Thrombectomy Platform (STEP) – Domain Clinical trials to be conducted in STEP: Stage 2 Protocol Application (OT2) OTA-24-010 The purpose of this research opportunity announcement (ROA) is to invite Stage 2 Protocol Applications for clinical trials that will address the indication expansion of current endovascular therapy (EVT) criteria, concomitant medical therapies added to EVT, novel EVT devices, and systems of care for EVT,to be conducted within the StrokeNet Thrombectomy Platform (STEP) within the NIH StrokeNet network. STEP Scott Janis, PhD
StrokeNet Thrombectomy Platform (STEP) – Domain Clinical trials to be conducted in STEP: Stage 1 Preliminary Application (OT2) OTA-24-009 The purpose of this research opportunity announcement (ROA) is to invite Stage 1 Preliminary Applications for clinical trials that will address the indication expansion of current endovascular therapy (EVT) criteria, concomitant medical therapies added to EVT, novel EVT devices, and(STEP) within the NIH StrokeNet network. STEP Scott Janis, PhD
Ultra-rare Gene-based Therapy (URGenT) Clinical Trials Conducted within NeuroNEXT: Stage 1 Preliminary Application (OT2) OTA-24-011 The purpose of this research opportunity announcement (ROA) is to invite Stage 1 Preliminary Applications for clinical trials of gene-based and gene-targeted therapies for ultra-rare neurological diseases, to be conducted within the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). NeuroNext Sophie (Hyun Joo) Cho, MD
Ultra-rare Gene-based Therapy (URGenT) Clinical Trials Conducted within NeuroNEXT: Stage 2 Protocol Application (OT2) OTA-24-012 The purpose of this research opportunity announcement (ROA) is to invite Stage 2 Protocol Applications for clinical trials of gene-based and gene-targeted therapies for ultra-rare neurological diseases, to be conducted within the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). NeuroNext Sophie (Hyun Joo) Cho, MD